Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRAL
NCT07840365Phase 3Recruiting
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban in Atrial fibrillation (AFib) (2 arms), sponsored by Texas Cardiac Arrhythmia Research Foundation. Primary endpoint: Composite endpoint of device-related thrombosis (DRT), thromboembolic events (TE) and major bleeding events at 3 years. Started Sep 2026; status: recruiting.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07840365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840365.